Teleflex Incorporated (NYSE:TFX) Stock Has Consensus Target Price of $154.40 According to Analysts

Teleflex Incorporated (NYSE:TFX) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $154.40.

Several analysts recently weighed in on TFX shares. Mizuho boosted their price objective on shares of Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Truist Financial lowered their target price on Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. UBS Group raised their target price on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Bank of America raised Teleflex from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $158.00 in a report on Monday, September 28th. Finally, Needham & Company LLC upped their price target on Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th.

Teleflex Stock Up 0.6%

NYSE TFX opened at $140.54 on Friday. The business has a fifty day moving average price of $131.39 and a two-hundred day moving average price of $125.19. The stock has a market capitalization of $5.95 billion, a PE ratio of 15.88, a PEG ratio of 0.93 and a beta of 0.83. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The firm had revenue of $570.33 million for the quarter, compared to analysts’ expectations of $559.59 million. During the same quarter in the previous year, the business posted $3.73 earnings per share. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities analysts expect that Teleflex will post 7.22 earnings per share for the current fiscal year.

Institutional Trading of Teleflex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TFX. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Teleflex in the 2nd quarter worth approximately $39,467,000. Fifth Third Bancorp raised its stake in Teleflex by 3,204.8% during the first quarter. Fifth Third Bancorp now owns 68,144 shares of the medical technology company’s stock worth $8,151,000 after buying an additional 66,082 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Teleflex during the second quarter worth $1,391,000. Irenic Capital Management LP bought a new position in Teleflex during the first quarter worth $104,061,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Teleflex during the second quarter worth $1,065,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.